Royalty Pharma Plc (RPRX)vsVertex Pharmaceuticals Inc (VRTX)
RPRX
Royalty Pharma Plc
$45.36
-0.37%
HEALTHCARE · Cap: $26.53B
VRTX
Vertex Pharmaceuticals Inc
$454.00
-0.88%
HEALTHCARE · Cap: $118.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 405% more annual revenue ($12.00B vs $2.38B). VRTX leads profitability with a 32.9% profit margin vs 32.4%. RPRX appears more attractively valued with a PEG of 1.39. VRTX earns a higher WallStSmart Score of 66/100 (B-).
RPRX
Buy61
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-17.3%
Fair Value
$37.74
Current Price
$45.36
$7.62 premium
Margin of Safety
+36.7%
Fair Value
$717.44
Current Price
$454.00
$263.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
RPRX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
RPRX generates stronger free cash flow (827M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 61/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?